Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up

Shahina Daar, Murtadha Al Khabori*, Sarah Al Rahbi, Moez Hassan, Abu Bakr El Tigani, Dudley J. Pennell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

The consequence of regular blood transfusion in patients with thalassemia major (TM) is iron overload. Herein, we report the long-term impact of chelation on liver iron concentration (LIC) and cardiac T2* MR in patients with TM. This is a retrospective cohort study over 10 years of adolescents and adults with TM aged at least 10 years who had their first cardiac T2* MR between September 2006 and February 2007. One-year chelation therapy was considered the unit of analysis. A total of 99 patients were included in this study with a median age of 18 years. The median cardiac T2* MR and LIC at baseline were 19 ms and 11.6 mg/g dw, respectively. During follow-up, 18 patients died and six underwent successful bone marrow transplantation. Factors associated with decreased survival were older age (HR 1.12, p = 0.014) and high risk cardiac T2* (HR 8.04, p = 0.004). The median cardiac T2* and LIC significantly improved over the 10-year follow-up period (p = 0.000011 and 0.00072, respectively). In conclusion, this long-term “real-life” study confirms that low cardiac T2* adversely impacts the overall survival in patients with TM. Higher baseline LIC predicts a larger reduction in LIC, and lower baseline cardiac T2* predicts a larger improvement in T2*.

Original languageEnglish
Pages (from-to)2009-2017
Number of pages9
JournalAnnals of Hematology
Volume99
Issue number9
DOIs
Publication statusPublished - Sep 1 2020
Externally publishedYes

Keywords

  • Heart
  • Iron overload
  • MRI T2*
  • Oman
  • Thalassemia

ASJC Scopus subject areas

  • Hematology

Cite this